Determination of drug-drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen

被引:1
作者
Mahfouz, Mona [1 ]
Alkhalid, Zaid Nabeel [1 ]
Birand, Nevzat [1 ,2 ,3 ]
机构
[1] Near East Univ, Fac Pharm, Dept Clin Pharm, Nicosia, Cyprus
[2] Cyprus Int Univ, Fac Pharm, Dept Clin Pharm, Nicosia, Cyprus
[3] Cyprus Int Univ, Fac Pharm, Dept Clin Pharm, CY-99258 Nicosia, Cyprus
关键词
Breast cancer; drug-drug interactions; cyclophosphamide; doxorubicin; chemotherapy;
D O I
10.1177/10781552231189700
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Drug interactions constitute a significant issue in cancer treatment. Therefore, it is important to assess and analyze all cancer patients' therapies prior to the initiation of chemotherapy. Methods A retrospective observational study was conducted at the Near East University Hospital Oncology Department located in North Cyprus between June 2019 and December 2021. The aim of the study was to determine the nature, type, and frequency of potential drug-drug interactions in breast cancer patients receiving a doxorubicin and cyclophosphamide regimen using Drugs.com, Lexicomp, and Micromedex databases while comparing the three electronic databases, according to the frequency, mechanism, and severity of drug-drug interactions. Results The study included 40 patients (44.4%) out of 90 patients diagnosed with breast cancer, as 50 patients (55.6%) who did not match the criteria were excluded. According to the Lexicomp database, 12 patients (30%) with breast cancer had 14 potential drug-drug interactions, according to the Drugs.com database, 15 patients (37.5%) with breast cancer had 22 potential drug-drug interactions, and according to the Micromedex database, 13 patients (32.5%) with breast cancer had 15 potential drug-drug interactions. Pearson correlation indicated a weak association (Lexicomp: r = 0.475, p = 0.002 and Micromedex: r = 0.491, p = 0.001) and a moderate association (Drugs.com: r = 0.500, p = 0.001) between potential drug-drug interactions and five or more medications. Conclusion This study showed that the Drugs.com database detected more potential drug interactions between chemotherapy and nonchemotherapy than the Lexicomp and Micromedex databases. Comprehensive drug review, use of electronic health record systems, and collaboration between healthcare providers such as pharmacists and physicians may be necessary strategies to minimize potential drug-drug interactions and optimize cancer treatment in patients with breast cancer.
引用
收藏
页码:830 / 843
页数:14
相关论文
共 50 条
[21]   Clinical Predictors of Chemotherapy-induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide [J].
Shih, Vivianne ;
Wan, Hee Siew ;
Chan, Alexandre .
ANNALS OF PHARMACOTHERAPY, 2009, 43 (03) :444-452
[22]   Review of drug-drug interactions in patients with prostate cancer [J].
Ruplin, Andrew ;
Segal, Eve ;
McFarlane, Tom .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (06) :1057-1072
[23]   Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction [J].
de Jonge, ME ;
Huitema, ADR ;
Rodenhuis, S ;
Beijnen, JH .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2004, 31 (02) :135-156
[24]   Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors [J].
Fogli, Stefano ;
Del Re, Marzia ;
Curigliano, Giuseppe ;
van Schaik, Ron H. ;
Lancellotti, Patrizio ;
Danesi, Romano .
CANCER TREATMENT REVIEWS, 2019, 74 :21-28
[25]   Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy [J].
Ku, Minhee ;
Je, Nam Kyung .
JOURNAL OF CHEMOTHERAPY, 2022, 34 (08) :534-542
[26]   Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer [J].
Vriens, B. E. P. J. ;
Aarts, M. J. B. ;
de Vries, B. ;
van Gastel, S. M. ;
Wals, J. ;
Smilde, T. J. ;
van Warmerdam, L. J. C. ;
de Boer, M. ;
van Spronsen, D. J. ;
Borm, G. F. ;
Tjan-Heijnen, V. C. G. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) :3102-3110
[27]   Drug-drug interactions in pediatric oncology patients [J].
Balk, T. E. ;
van der Sijs, I. H. ;
van Gelder, T. ;
Janssen, J. J. B. ;
van der Sluis, I. M. ;
van Leeuwen, R. W. F. ;
Engels, F. K. .
PEDIATRIC BLOOD & CANCER, 2017, 64 (07)
[28]   Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [J].
Butters, Daria J. ;
Ghersi, Davina ;
Wilcken, Nicholas ;
Kirk, Steven J. ;
Mallon, Peter T. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (11)
[29]   An Evaluation of Hepatotoxicity in Breast Cancer Patients Receiving Injection Doxorubicin [J].
Damodar, G. ;
Smitha, T. ;
Gopinath, S. ;
Vijayakumar, S. ;
Rao, Y. A. .
ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2014, 4 (01) :74-79
[30]   A survey on gastrointestinal adverse drug reactions of Doxorubicin and Cyclophosphamide combination therapy [J].
Jamali, Jameela ;
Dayo, Abdullah ;
Adeel, Arshia ;
Qureshi, Yasmeen ;
Khan, Tooba ;
Begum, Sania .
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2018, 68 (06) :926-928